Amyloids in the brain may reaccumulate in AD patients after lecanemab withdrawal

April 15, 2022

1 minute watch



Healio interview.

Disclosures: Swanson is employed by Eisai Inc.

We have not been able to process your request. Please try again later. If you continue to have this problem, please contact [email protected]

Alzheimer’s disease patients who are treated with lecanemab have shown the potential to reaccumulate brain amyloid after drug withdrawal, said a speaker at the 2022 annual meeting of the American Academy of Neurology.

“Lecanemab produces a very robust reduction in brain amyloid with time and dose, and this correlates with slowing clinical decline,” Chad Swanson, Ph.D.executive director of the Neurology Business Group at Eisai Inc., said.

Lecanemab is being developed by Eisai and Biogen for patients with early AD.

About Hector Hedgepeth

Check Also

New study challenges widely held beliefs about Alzheimer’s disease

A new study challenges the dogma behind drug trials for Alzheimer’s disease. The study found …